Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Daiichi-Sankyo Slashing 1,000+ US Jobs Ahead Of Benicar Expiry

This article was originally published in PharmAsia News

Executive Summary

Japanese major Daiichi-Sankyo is preparing to cut up to 1,200 mainly sales positions in the US ahead of the loss of exclusivity for blockbuster antihypertensive Benicar, and amid a shift in its business model away from primary care and toward specialty products.


Related Content

Daiichi Closing Indian Site As Global Restructuring Continues


Related Companies